---
title: "Morgan Stanley: Expects WUXI BIO stock price to rise in the next 45 days, target price raised to HKD 50"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275690983.md"
description: "Morgan Stanley released a research report stating that it expects WuXi Biologics' stock price to rise in the next 45 days, with a probability estimated between 70% and 80%. Based on the accelerated revenue growth and margin expansion of WuXi Biologics, the bank has raised its earnings forecast for 2026 to 2030 by 4% to 10%, increasing the target price from HKD 45 to HKD 50, maintaining an \"Overweight\" rating. The company previously issued a positive profit alert, with management indicating that growth will accelerate in the fiscal year 2026, along with a 16% increase in the number of integration projects in 2025, and strong momentum in research services, all reflecting that the company's performance in 2026 will be robust. Additionally, the momentum in research services is expected to generate revenue related to IP, further enhancing profitability. The company has also recently reached external licensing agreements with Vertex and ZAI LAB. Furthermore, WuXi Biologics anticipates strong growth in its manufacturing segment and mentioned \"multiple blockbuster drugs are expected.\" The company completed 28 process performance qualifications (PPQ) in 2025, a year-on-year increase of 75%; the bank views this as a leading indicator for future commercialization contracts"
datetime: "2026-02-12T02:49:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275690983.md)
  - [en](https://longbridge.com/en/news/275690983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275690983.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275690983.md) | [繁體中文](https://longbridge.com/zh-HK/news/275690983.md)


# Morgan Stanley: Expects WUXI BIO stock price to rise in the next 45 days, target price raised to HKD 50

According to the Zhitong Finance APP, Morgan Stanley released a research report stating that it expects WuXi Biologics (02269) stock price to rise in the next 45 days, with a probability of occurrence estimated between 70% and 80%. Based on the accelerated revenue growth and margin expansion of WuXi Biologics, the bank has raised its earnings forecast for 2026 to 2030 by 4% to 10%, increasing the target price from HKD 45 to HKD 50, maintaining an "Overweight" rating.

The company previously issued a positive profit alert, and management indicated at an event that growth would accelerate in the fiscal year 2026. Additionally, the number of integration projects for 2025 is expected to increase by 16%, along with strong momentum in research services, all reflecting that the company's performance in 2026 will be strong. Meanwhile, the momentum in research services is expected to generate revenue related to IP, further enhancing profitability. The company has also recently reached an external licensing agreement with Vertex and ZAI LAB (09688).

Furthermore, WuXi Biologics anticipates strong growth in the manufacturing sector and mentioned that "multiple blockbuster drugs are expected." The company completed 28 process performance qualifications (PPQ) in 2025, a year-on-year increase of 75%; the bank views this as a leading indicator for future commercialization contracts

### 相关股票

- [WUXI BIO (02269.HK)](https://longbridge.com/zh-CN/quote/02269.HK.md)
- [ZAI LAB (09688.HK)](https://longbridge.com/zh-CN/quote/09688.HK.md)

## 相关资讯与研究

- [Zai Lab Expands Employee Equity Awards Under 2024 Incentive Plan](https://longbridge.com/zh-CN/news/281557795.md)
- [Morgan Stanley's long position in Wuxi Biologics (Cayman) decreases to 2.11% on Jan 20 from 5.58%, HKEX shows](https://longbridge.com/zh-CN/news/273496397.md)
- [BullFrog AI Signs Major AI Drug Discovery Partnership](https://longbridge.com/zh-CN/news/281092205.md)
- [14:37 ETLevrx and Waltz Health Partner to Expand Access to Transparent Pharmacy Pricing](https://longbridge.com/zh-CN/news/281411704.md)
- [TippingPoint Biosciences Raises $4.5M Seed to Drug Hidden Epigenetic Targets in Deadly Pediatric Brain Cancer](https://longbridge.com/zh-CN/news/281175947.md)